Drug-Resistant Pulmonary Tuberculosis in HIV/AIDS Patients: Clinical Manifestations and Treatment Outcomes
Tuberculosis, Lung Diseases, HIV Infection · 06.11.2026 · (4) · 61-69
DOI: 10.30978/tb2026-4-61 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tuberculosis, Lung Diseases, HIV Infection, online erschienen am 06.11.2026. Verfasst von Z.I. Piskur und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Co-infection of tuberculosis (TB) and human immunodeficiency virus (HIV) creates a deadly combination, increasing susceptibility to disease progression. Objective — to analyze clinical manifestations and treatment outcomes of drug-resistant (DR) pulmonary (PTB) in patients with HIV/AIDS. Materials and methods. We retrospectively analysed the medical files of patients with HIV/AIDS-DR-PTB (n = 61) and drug-susceptible (DS) PTB (HIV/AIDS-DS-PTB; n = 49). Results and discussion. A total of 9.8 % of patients with HIV/AIDS-DR-PTB were hospitalised in serious condition and had a longer mean hospital stay (61.7 vs. 23.1 days). HIV/AIDS-DR-PTB was more likely to lead to a fatal outcome (26.2 % vs.11.9 %). Mycobacterium tuberculosis resistance to R was more common than resistance to HRZE and Pre-Extensively resistance (34.4 % vs. both 18.0 %; p < 0.05). Disseminated PTB, destructive lesions were more frequently diagnosed in patients with HIV/AIDS-DR-PTB. A destructive process was detected 1.8 times more frequently in patients with HIV/AIDS-DR-PTB (52.1 % vs. 29.3 %). HIV/AIDS-DR-PTB was often complicated by intoxication and cachexia. HIV/AIDS-DR-PTB was often complicated by intoxication/cachexia (54.1 % vs. 28.0 %; p < 0.01). Respiratory failure was significantly more common in HIV/AIDS-DR-PTB patients (90.2 % vs. 59.5 %; p < 0.01), which occurred on background of PTB with chronic bronchitis (60.7 % vs. 33.3 %; p < 0.01). Cerebral cryptococcosis (32.8 % vs. 9.5 %; p < 0.01) and spastic tetraplegia (9.8 % vs. 0 %; p < 0.05) were more frequently detected in patients with HIV/AIDS-DR-PTB. Conclusions. The results showed a high rate of multidrug resistance (42.6 %). Severe intoxication, cachexia, chronic bronchitis, and respiratory failure were associated with the development of DR-PTB. HIV/AIDS-associated DR-PTB led to disability in 55.7 %, with mortality 2.2 times. Disseminated PTB and destructive lesions were more frequently diagnosed in HIV/AIDS-associated DR-PTB patients.
Zitieren
APA
Piskur, Z., Pylypiv, L., Sakhelashvili, M., & Chulovska, U. (2026). Drug-Resistant Pulmonary Tuberculosis in HIV/AIDS Patients: Clinical Manifestations and Treatment Outcomes. Tuberculosis, Lung Diseases, HIV Infection, 61-69. https://doi.org/10.30978/tb2026-4-61
Vancouver
Piskur Z, Pylypiv L, Sakhelashvili M, Chulovska U. Drug-Resistant Pulmonary Tuberculosis in HIV/AIDS Patients: Clinical Manifestations and Treatment Outcomes. Tuberculosis, Lung Diseases, HIV Infection. 2026:61-69. doi:10.30978/tb2026-4-61
BibTeX
@article{Piskur2026,
author = {Piskur, Z.I. and Pylypiv, L.I. and Sakhelashvili, M.I. and Chulovska, U.B.},
title = {Drug-Resistant Pulmonary Tuberculosis in HIV/AIDS Patients: Clinical Manifestations and Treatment Outcomes},
journal = {Tuberculosis, Lung Diseases, HIV Infection},
year = {2026},
number = {4},
pages = {61--69},
doi = {10.30978/tb2026-4-61}
}
EUVIMED